Frontline therapy with bendamustine rituximab (BR) and rituximab cyclophosphamide vincristine prednisone (RCVP) confers similar long-term outcomes in patients with treatment naïve Waldenström macroglobulinemia in a real-world setting: a population-based analysis-Reference-Cited by-同舟云学术

Frontline therapy with bendamustine rituximab (BR) and rituximab cyclophosphamide vincristine prednisone (RCVP) confers similar long-term outcomes in patients with treatment naïve Waldenström macroglobulinemia in a real-world setting: a population-based analysis

Published:2023-12-29 Issue: Volume: Page:1-7
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Kim Jowon Laura¹^ORCID,Gerrie Alina S.²^ORCID,Savage Kerry Joane²^ORCID,Villa Diego²^ORCID,Scott David²^ORCID,Craig Jeffrey W.³^ORCID,Farinha Pedro³^ORCID,Skinnider Brian³,Slack Graham³,Connors Joseph M²^ORCID,Sehn Laurie H.²^ORCID,Venner Christopher²^ORCID,Freeman Ciara L.⁴^ORCID

Affiliation:

1. UBC, Department of Medicine, Vancouver, Canada

2. BC Cancer Agency, Centre for Lymphoid Cancer and Department of Medical Oncology, Vancouver, Canada

3. BC Cancer Agency, Centre for Lymphoid Cancer and Department of Pathology, Vancouver, Canada

4. Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL, USA

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2023.2290466

Reference9 articles.

1. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

2. Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus

3. Phase III Study of R-CVP Compared With Cyclophosphamide, Vincristine, and Prednisone Alone in Patients With Previously Untreated Advanced Follicular Lymphoma

4. Two Years Rituximab Maintenance Vs. Observation after First Line Treatment with Bendamustine Plus Rituximab (B-R) in Patients with Waldenström's Macroglobulinemia (MW): Results of a Prospective, Randomized, Multicenter Phase 3 Study (the StiL NHL7-2008 MAINTAIN trial)

5. Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cyclophosphamide Pharmacogenomic Variation in Cancer Treatment and Its Effect on Bioactivation and Pharmacokinetics;Advances in Pharmacological and Pharmaceutical Sciences;2024-01